BACKGROUND: Osteopenia has been described in HIV-infected persons, but most studies have not focused on aging men, have not included an HIV-negative comparison group with similar risks to those of the HIV-infected men, or lacked data on fracture rates. METHODS: We analyzed bone mineral density (BMD) and incident fractures in 559 men who were >or= 49 years old with or at-risk for HIV, including 328 with and 231 without HIV infection. RESULTS: Median age was 55 years, 56% were black and 89% had used illicit drugs. In unadjusted analysis, BMD was lower in HIV-infected compared with HIV-uninfected men at the femoral neck (0.97 +/- 0.14 versus 1.00 +/- 0.15 g/cm; P < 0.05) and lumbar spine (1.17 +/- 0.20 versus 1.20 +/- 0.21 g/cm; P = 0.06); both differences were significant (P < 0.05) after adjusting for age, weight, race, testosterone level, and prednisone and illicit drug use. Non-black race and body weight were independently associated with BMD at both measurement sites and methadone therapy was independently associated with spine BMD. Among HIV-infected men, 87% had taken antiretrovirals and 74% had taken protease inhibitors, but their use was not associated with BMD. Among men who had at least one subsequent study visit (94%), incident fracture rates per 100 person-years differed among men with normal BMD, osteopenia and osteoporosis (1.4 versus 3.6 versus 6.5; P < 0.01). A 38% increase in fracture rate among HIV-infected men was not statistically significant. CONCLUSIONS: HIV infection is independently associated with modestly reduced BMD in aging men, and decreased BMD is associated with increased fracture risk.
BACKGROUND:Osteopenia has been described in HIV-infectedpersons, but most studies have not focused on aging men, have not included an HIV-negative comparison group with similar risks to those of the HIV-infectedmen, or lacked data on fracture rates. METHODS: We analyzed bone mineral density (BMD) and incident fractures in 559 men who were >or= 49 years old with or at-risk for HIV, including 328 with and 231 without HIV infection. RESULTS: Median age was 55 years, 56% were black and 89% had used illicit drugs. In unadjusted analysis, BMD was lower in HIV-infected compared with HIV-uninfectedmen at the femoral neck (0.97 +/- 0.14 versus 1.00 +/- 0.15 g/cm; P < 0.05) and lumbar spine (1.17 +/- 0.20 versus 1.20 +/- 0.21 g/cm; P = 0.06); both differences were significant (P < 0.05) after adjusting for age, weight, race, testosterone level, and prednisone and illicit drug use. Non-black race and body weight were independently associated with BMD at both measurement sites and methadone therapy was independently associated with spine BMD. Among HIV-infectedmen, 87% had taken antiretrovirals and 74% had taken protease inhibitors, but their use was not associated with BMD. Among men who had at least one subsequent study visit (94%), incident fracture rates per 100 person-years differed among men with normal BMD, osteopenia and osteoporosis (1.4 versus 3.6 versus 6.5; P < 0.01). A 38% increase in fracture rate among HIV-infectedmen was not statistically significant. CONCLUSIONS:HIV infection is independently associated with modestly reduced BMD in aging men, and decreased BMD is associated with increased fracture risk.
Authors: W Willett; M J Stampfer; C Bain; R Lipnick; F E Speizer; B Rosner; D Cramer; C H Hennekens Journal: Am J Epidemiol Date: 1983-06 Impact factor: 4.897
Authors: S Landonio; T Quirino; P Bonfanti; A Gabris; L Boccassini; C Gulisano; L Vulpio; E Ricci; M Carrabba; G M Vigevani Journal: Biomed Pharmacother Date: 2004-11 Impact factor: 6.529
Authors: Joel E Gallant; Schlomo Staszewski; Anton L Pozniak; Edwin DeJesus; Jamal M A H Suleiman; Michael D Miller; Dion F Coakley; Biao Lu; John J Toole; Andrew K Cheng Journal: JAMA Date: 2004-07-14 Impact factor: 56.272
Authors: Todd T Brown; Mary D Ruppe; Rory Kassner; Princy Kumar; Theresa Kehoe; Adrian S Dobs; Joseph Timpone Journal: J Clin Endocrinol Metab Date: 2004-03 Impact factor: 5.958
Authors: Clara Y Jones; Joseph W Hogan; Brad Snyder; Robert S Klein; Anne Rompalo; Paula Schuman; Charles C Carpenter Journal: Clin Infect Dis Date: 2003 Impact factor: 9.079
Authors: Sara E Dolan; Jeannie S Huang; Kathleen M Killilea; Meghan P Sullivan; Negar Aliabadi; Steven Grinspoon Journal: AIDS Date: 2004-02-20 Impact factor: 4.177
Authors: C Amiel; A Ostertag; L Slama; C Baudoin; T N'Guyen; E Lajeunie; L Neit-Ngeilh; W Rozenbaum; M C De Vernejoul Journal: J Bone Miner Res Date: 2003-12-22 Impact factor: 6.741
Authors: E M Stein; M T Yin; D J McMahon; A Shu; C A Zhang; D C Ferris; I Colon; J F Dobkin; S M Hammer; E Shane Journal: Osteoporos Int Date: 2010-06-29 Impact factor: 4.507
Authors: Anda Gonciulea; Ruibin Wang; Keri N Althoff; Michelle M Estrella; Deborah E Sellmeyer; Frank J Palella; Jordan E Lake; Lawrence A Kingsley; Todd T Brown Journal: J Acquir Immune Defic Syndr Date: 2019-07-01 Impact factor: 3.731
Authors: Michael T Yin; Don J McMahon; David C Ferris; Chiyuan A Zhang; Aimee Shu; Ronald Staron; Ivelisse Colon; Jeffrey Laurence; Jay F Dobkin; Scott M Hammer; Elizabeth Shane Journal: J Clin Endocrinol Metab Date: 2009-12-04 Impact factor: 5.958